(HealthDay)—For children with B-cell precursor acute lymphoblastic leukemia with late bone marrow relapse, risk stratification by minimal residual disease seems to be an effective strategy for treatment, according to a ...
Mar 19, 2019
0
2
The survival of patients with pediatric acute lymphoblastic leukemia (ALL) has significantly improved in the last several decades. However, novel strategies to identify cases that are likely to respond poorly to treatment ...
Oct 24, 2019
0
4
Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men. While patients have access to more quality ...
May 10, 2018
0
7
A new study on how the progression of acute lymphocytic leukemia (ALL) is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin (OPN) may be ...
Apr 15, 2013
0
0
For patients with newly diagnosed multiple myeloma (MM), mass spectrometry (MS) can monitor treatment response, according to a study published online Jan. 4 in Blood Cancer Journal.
Jan 19, 2023
0
18
(HealthDay)—The detection of molecular minimal residual disease is associated with increased relapse rates in acute myeloid leukemia (AML), according to a study published in the March 29 issue of the New England Journal ...
Mar 29, 2018
0
3
McMaster University researcher Sheila Singh and her team have discovered how glioblastoma, a lethal brain cancer, can evade treatments and kill.
Sep 29, 2022
0
69
For patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTNT), according to a study published online ...
Mar 22, 2023
0
2
(HealthDay)—Combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) plus stem-cell transplantation is associated with longer progression-free survival than RVD alone for adults with multiple myeloma, ...
Apr 7, 2017
0
2
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients—aged 16 to 39 with acute lymphoblastic leukemia (ALL)—tend to fare better when treated with high-intensity ...
Dec 7, 2014
0
0
